PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Selegiline and Mirtazapine Interaction

Drug interaction information between Selegiline and Mirtazapine.

Selegiline and Mirtazapine have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Selegiline and Mirtazapine. Major interactions are generally avoided, moderate ones may need monitoring or a dose adjustment, and minor ones are usually low-risk. This page shows the documented mechanism and guidance. Label-documented interactions are not a complete safety review, so always confirm your own medications with a pharmacist or doctor. Educational information, not medical advice.

Drug A

Selegiline

Selective MAO-B Inhibitor

Drug B

Mirtazapine

Noradrenergic and Specific Serotonergic Antidepressant (NaSSA)

How They Interact

Both mirtazapine and selegiline increase the amount of serotonin in your brain. Combining them can lead to a toxic buildup of this chemical.

What To Do

This combination should be avoided. Your doctor may need to adjust your dosages or monitor you very closely.

FDA Label Information

Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact The concomitant use of serotonergic drugs with mirtazapine increases the risk of serotonin syndrome.

Mirtazapine Also Interacts With

View all Mirtazapine interactions →

Frequently Asked Questions

Can I take Selegiline and Mirtazapine together?

This is a moderate interaction. This combination should be avoided. Your doctor may need to adjust your dosages or monitor you very closely.

How serious is the interaction between Selegiline and Mirtazapine?

This interaction is classified as "moderate" severity by the FDA. Moderate interactions may worsen your condition or change how your medications work.

Why do Selegiline and Mirtazapine interact?

Both mirtazapine and selegiline increase the amount of serotonin in your brain. Combining them can lead to a toxic buildup of this chemical.

Understanding the Selegiline and Mirtazapine Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Selegiline belongs to the Selective MAO-B Inhibitor class and Mirtazapine belongs to the Noradrenergic and Specific Serotonergic Antidepressant (NaSSA) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both mirtazapine and selegiline increase the amount of serotonin in your brain. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Selegiline has 9 total documented interactions on file in this dataset, and Mirtazapine has 29. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: This combination should be avoided. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Selegiline or Mirtazapine based on a web page, speak with your prescriber or pharmacist before making any change.

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. Always consult your healthcare provider about drug interactions.